Navigation Links
Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709

High Concentrations Reached in Key Lung Compartments

REINACH and BASEL, Switzerland, March 29, 2007 /PRNewswire-FirstCall/ -- Arpida Ltd. today announced promising results of "first-in-man" studies with AR-709. These radiolabelled Human Microdose studies included a total of 19 healthy male volunteers.

This groundbreaking study is the first ever using Microdosing for the determination of drug concentrations in lung compartments. The results showed that AR-709 achieves high concentrations in bronchial mucosa (BM), epithelial lining fluid (ELF) and alveolar macrophages (AM), the three key compartments of the lungs where pathogens can reside and replicate. Moreover, the results of the studies show that AR-709 exhibited a large volume of distribution and a long half life in man. Oral bioavailability was potentially low but this could be due to the low dose, poor absorption or extensive metabolism.

The studies were conducted at Hammersmith Medicines Research Ltd (London, UK) under MHRA regulatory authorisation and were coordinated by Xceleron Ltd (York, UK), the exploratory clinical development specialist and world leader in the field of Human Microdosing.

Dr Sergio Lociuro, Head of Research of Arpida Ltd. commented "I am very pleased with the results of this first human trial with AR-709. They clearly show that the compound distributes well throughout the body and more importantly in the lungs. In a substantial number of cases, community-acquired respiratory tract infections, caused by S. pneumoniae, require hospitalisation and intravenous therapy. AR-709 appears to have the necessary characteristics to eradicate the microorganisms that can result in serious infections. For cases not requiring hospitalisation and/or to accelerate patient discharge from the hospital, targeted delivery, e.g. via inhalation, could provide a valid and promising alternative to administration via the oral route. Altho
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Arpida adds novel antibiotic AR-2474 to its preclinical pipeline
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Arpida Announces Promising Results First Man Studies With
(Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
(Date:7/10/2014)... 10, 2014  RESMED INC. (NYSE: RMD ) ... fiscal year ended June 30, 2014 results on Thursday, July ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the largest ... MiE America , Inc., a leading provider of Siemens ... a long-term agreement naming BC Technical as the authorized ... MiE and BC Technical announced today that ... establish BC Technical as the service and systems provider ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... SAN DIEGO, June 8, 2011 Amylin Pharmaceuticals, Inc. (NASDAQ: ... the following statement regarding the decision of the United States ... its motion for a preliminary injunction to enjoin Eli Lilly ... in anticompetitive activity and breaching its diabetes collaboration agreement with ...
... CAMBRIDGE, Mass., June 8, 2011 Regulus Therapeutics ... development of innovative medicines targeting microRNAs, and Alnylam Pharmaceuticals, ... therapeutics company, today announced the publication in ... about the antagonism of microRNA-103 and microRNA-107 (miR-103/107). Data ...
Cached Medicine Technology:Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order 2Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order 3Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order 4Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 2Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 3Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 4Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 5Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 6Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 7
(Date:7/10/2014)... One week ahead of its annual Board meeting, ... will extend compensation benefits to workers from two months’ ... as a result of factory remediation, effective immediately. ... the closure of five factories for remediation. Structural faults ... concerns. In May, the Alliance—in a 50/50 partnership with ...
(Date:7/10/2014)... In his latest blog post at http://www.perwickstrom.com , ... Wickstrom has listed 5 ways to follow-up without being ... get information or sometimes even just return an inquiry, ... a skill that most people don’t have,” commented Per ... dialogue moving without coming across as annoying – let ...
(Date:7/10/2014)... Redwood City, CA (PRWEB) July 10, 2014 ... Management, announced the latest results of the 4th ... the "Source-to-Pay” suite model. , Every day ... supplier data, contracts, expense forms etc. To meet ... deploying "Source-to-Pay" (S2P) suites which can be defined ...
(Date:7/10/2014)... professional football players who have shoulder stabilization surgery are ... finds. Shoulder instability is a common injury among ... to fix the problem has been unclear, the study ... who had shoulder stabilization surgery. Ninety percent of those ... as playing in at least one regular season game. ...
(Date:7/10/2014)... 10, 2014 (HealthDay News) -- Men who have a ... cancer, a new study suggests. But the risk ... not involved with the study said more research is ... accurate. For the study, Harvard researchers analyzed data ... for 24 years, starting in 1986. During that time, ...
Breaking Medicine News(10 mins):Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3Health News:Shoulder Surgery Gets NFL Players Back in the Game 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3
... rapidly changing the clinical practice of oncology. As scientists ... development of new tools capable of multiple, inexpensive biomarker ... essential to the success of genetically informed and personalized ... now developed a microfluidic image cytometry (MIC) platform that ...
... a single rock being overturned or an entire mountaintop ... processes, and vice versa. Ecological scientists will discuss findings ... growth to the diversity of insect species on green ... buildingsat the Ecological Society of America,s 95th Annual Meeting ...
... , , , , , ... , , AUDIO: ... School of Medicine... , Click here for more information. ... , , , , , ...
... HealthDay Reporter , MONDAY, August 2 (HealthDay News) -- ... than normal are at greater risk of developing artery-clogging ... of the arteries leading to heart disease, a new ... common assumption that modestly high cholesterol levels are nothing ...
... August 2, 2010 From the many images sent home ... viewed the plight of their country,s combat-weary veterans as stark ... But recent research at Washington State University (WSU) suggests that, ... often sets the trajectory of the balance of their lives. ...
... PICK: Boosting the efficacy of anticancer vaccines ... anticancer vaccines, which are designed to boost the patient,s ... example, the viruses used to deliver the tumor protein ... the patient,s immune system, inducing neutralizing and suppressive responses. ...
Cached Medicine News:Health News:New diagnostic chip able to generate single-cell molecular 'fingerprints' for brain tumors 2Health News:New diagnostic chip able to generate single-cell molecular 'fingerprints' for brain tumors 3Health News:Scientists unravel human-ecosystem interactions 2Health News:Scientists unravel human-ecosystem interactions 3Health News:Scientists unravel human-ecosystem interactions 4Health News:Colitis patients diagnosed later in life tend to have better disease outcomes 2Health News:Colitis patients diagnosed later in life tend to have better disease outcomes 3Health News:Colitis patients diagnosed later in life tend to have better disease outcomes 4Health News:High Cholesterol in Youth Boosts Heart Risk In Middle Age 2Health News:High Cholesterol in Youth Boosts Heart Risk In Middle Age 3Health News:High Cholesterol in Youth Boosts Heart Risk In Middle Age 4Health News:Sociologist finds combat veterans face more lifelong socioeconomic challenges 2Health News:JCI online early table of contents: August 2, 2010 2Health News:JCI online early table of contents: August 2, 2010 3Health News:JCI online early table of contents: August 2, 2010 4Health News:JCI online early table of contents: August 2, 2010 5Health News:JCI online early table of contents: August 2, 2010 6
Optimized 180W Xenon lamp, low fan noise with reduced air turbulence, compact housing. Built for monitor applications and all endoscope dimensions. Ideal for video recording applications....
High-intensity 300-watt xenon lamp, with continuously adjustable output from 0 to 100% manually or automatically by camera video output signal....
Integrated electronics, single-chip CCD camera with PAL and NTSC output. PAL output at 460 lines, NTSC output at 470 lines. 30mm focal length. 90mm length x 20mm diameter....
Integrated electronics, single-chip CCD camera with PAL and NTSC output. PAL output at 625 lines, NTSC output at 525 lines. 23mm focal length. Output via Y/C mini-DIN-4 port. 135mm length x 44mm ...
Medicine Products: